Mechanism of Action of Donanemab-azbt for Alzhenimer’s
Donanemab got FDA approval on 2nd July 2024. The mechanism of action of Donanemab-azbt (Kisunla) is detailed here to understand how this new molecule can be a life-changer for people with Alzheimer’s disease. Kisunla (Donanemab) is a special type of medicine known as a monoclonal antibody. Monoclonal antibodies are lab-made molecules designed to fight diseases … Read more